India’s National Stock Exchange has received more than $10 billion in investor bids for its $2.3 billion initial public offering, underscoring the strength of demand for exposure to the country’s rapidly expanding retail investment market even as the exchange commands a valuation well above major U.S. peers.

Investors bid for 505.81 million NSE shares on Monday, 5.7 times the 88.64 million shares on offer, according to the IPO data. Demand has been particularly strong among institutional and high-net-worth investors, highlighting the appetite for one of India’s most closely watched listings.

The exchange had already raised 67.5 billion rupees, or about $704 million, from anchor investors last week. The group included the Monetary Authority of Singapore, the Abu Dhabi Investment Authority and Life Insurance Corporation of India.

The offering is India’s largest IPO so far this year and the country’s second-largest ever, behind Hyundai Motor India’s $3.3 billion listing in 2024. The NSE’s public-market debut has also been unusually long in the making, with preparations for a listing stretching back to 2016.

The scale of demand is notable because investors are being asked to pay a substantial premium for the exchange. NSE is valued at about 42.9 times earnings based on the upper end of its IPO price band and earnings per share for the year ended March 2026, according to Yes Securities.

That compares with price-to-earnings ratios of less than 24 times for U.S. stock-exchange companies. Nasdaq trades at about 23.6 times earnings, while Intercontinental Exchange trades at 21.9 times, according to LSEG data. The valuation gap means investors are effectively paying more for NSE’s exposure to India’s capital-market expansion than they are for established U.S. exchange operators.

The rationale for that premium rests largely on NSE’s dominant position and the potential growth of India’s investor base.

NSE controls about 93% of India’s cash equity market and almost 100% of equity futures trading, alongside roughly 75% of equity options trading, according to its IPO filing. India itself has become one of the world’s 10 largest equity markets, with total market capitalization of around 492 trillion rupees, or $5.1 trillion.

That market is also becoming increasingly important to Indian households.

India’s latest Economic Survey said equity investments, previously a relatively small component of household balance sheets, had become a “significant component of financial wealth.” The share of equities and mutual funds in annual household financial savings rose to 15.2% in the financial year ended March 2025, from just 2% in the financial year ended March 2012.

For NSE, that shift creates a potentially powerful structural tailwind. More households participating in equities can translate into higher trading activity, greater derivatives participation and a broader base of investors using the exchange’s infrastructure.

The exchange’s business model adds another attraction. Indian brokerage Geojit Financial Services described NSE as having an “asset-light business model” that supports consistently high margins and cash generation. The brokerage also pointed to rising capital-market participation and what it called increasing “financialization” as providing a long-term growth opportunity.

The key question for investors is whether those growth prospects justify paying almost twice the earnings multiple of some major U.S. exchange operators.

Exchange businesses generally benefit from scale because additional trading volumes can generate revenue without requiring a proportional increase in physical infrastructure. That characteristic can produce strong cash generation when participation and market activity expand.

NSE’s dominance in derivatives gives it another source of revenue and market activity. Equity options have become essential to India’s retail trading boom, although the rapid growth of derivatives also creates regulatory and sustainability questions around retail participation.

The exchange is therefore more than a conventional stock-market infrastructure company. Its valuation is also a bet on continued growth in India’s household participation in financial markets.

There are signs that the potential investor base remains far from saturated. Sundararaman Ramamurthy, managing director of NSE rival Bombay Stock Exchange, said earlier this year that 35 million investors had registered on his platform in 2025 and that a “significant amount of population” had yet to enter the capital markets.

That expansion could support NSE even if foreign investors remain volatile. Ramamurthy has argued that the growing participation of domestic investors helped shield Indian markets from a sharper decline during periods when foreign investors were selling heavily.

The gap between domestic and foreign capital has become an issue for India’s equity market. A larger domestic investor base can provide a more stable source of liquidity and reduce the market’s dependence on global portfolio flows, although it does not eliminate exposure to global risk-off episodes.

For the NSE IPO, the immediate demand is clear. The bigger test will come after the listing, when investors will have to justify the premium valuation through earnings growth and continued expansion of trading activity.

The 5.7-times subscription level suggests that investors are willing to pay for NSE’s market dominance and India’s financialization story. But the comparison with Nasdaq and Intercontinental Exchange shows how much optimism is already embedded in the price.

Thus, investors are not simply buying an exchange. They are paying a premium for a dominant financial infrastructure business at a time when more Indian households are shifting their savings toward equities and other market-based investments. Whether that structural growth can sustain the valuation will become clearer once the company begins trading publicly.

Iambic Therapeutics, a drug developer backed by Nvidia and Qatar’s sovereign wealth fund, has filed for a U.S. initial public offering, adding another biotechnology company to an increasingly active fall pipeline and highlighting the sector’s relative resilience as other parts of the IPO market face rising borrowing costs and geopolitical uncertainty.

The San Diego-based company filed on Monday after two other drug developers, Retension Pharmaceuticals and TRex Bio, submitted IPO paperwork on Friday. ADARx Pharmaceuticals also began its roadshow on Monday, adding to a cluster of biotech listings and planned offerings.

The activity stands out against a more difficult backdrop for new stock offerings. The fall IPO market has faced uncertainty linked to the Iran war, higher bond yields, interest-rate increases, and concerns about how artificial intelligence could disrupt established industries.

Biotech has been less exposed to those pressures, according to IPO analysts, helped in part by continued acquisition activity from large pharmaceutical companies seeking new drugs and promising clinical programs.

“All five of the year’s best-performing IPOs ($50 million deal size and above) are biotechs. Much of that is being driven by drug advancement and M&A,” said Matt Kennedy, senior strategist at Renaissance Capital, which tracks IPOs and manages IPO-focused funds.

Iambic’s offering adds another dimension to the biotech boom because the company is built around the use of artificial intelligence in drug discovery.

Founded in 2019 as Entos, Iambic is developing drug candidates for solid tumors using an AI platform designed to accelerate the discovery of small-molecule therapies. Its most advanced candidate, IAM1363, is being tested in an early-stage clinical trial for solid tumors including breast cancer. The program remains at an early stage, meaning investors will ultimately have to assess the company’s value against the substantial clinical and regulatory risks associated with drug development.

The IPO filing comes on the same day that Iambic announced a multi-year collaboration with AbbVie to accelerate AI-driven discovery of small-molecule medicines.

The agreement expands a partnership network that already includes Takeda, Lundbeck, Revolution Medicines, Jazz Pharmaceuticals and Bayer. The breadth of those relationships provides Iambic with commercial validation for its drug-discovery platform, although partnerships do not guarantee that experimental medicines will successfully reach the market.

Iambic has raised about $461.8 million from technology and healthcare investors since its founding. Its backers include Nvidia and Qatar Investment Authority, alongside Catalio, Nexus Ventures and Coatue Management.

Nvidia’s involvement is notable because the chipmaker has become one of the central financial and technological beneficiaries of the AI boom. Its investment in Iambic extends that exposure beyond computing infrastructure into an industry where AI is being used to shorten parts of the drug-development process.

For investors, that creates a potentially attractive but difficult proposition. AI can help pharmaceutical researchers process biological data, identify potential compounds and improve parts of the drug-discovery workflow, but the technology does not remove the lengthy clinical testing and regulatory process that determines whether a drug can become commercially viable.

Iambic’s most advanced program therefore remains the critical factor for public-market investors. A successful clinical development path could give the company significant value, while disappointing results could quickly undermine the investment case.

The timing of the IPO also matters. Biotechnology companies have historically been sensitive to financing conditions because many developers operate for years before generating meaningful product revenue. Higher interest rates can therefore increase the cost of capital and make speculative growth companies less attractive.

Yet the current biotech IPO pipeline suggests investors remain willing to fund companies with promising clinical programs, particularly where there is a credible path to acquisition by larger pharmaceutical companies. That acquisition backdrop has become more relevant for the sector. Large drugmakers face pressure to replenish pipelines as existing products mature, creating demand for smaller biotechnology companies with promising therapies and technology platforms.

Iambic is attempting to position itself at the intersection of those trends. Its partnerships give it access to established pharmaceutical companies, while its AI platform offers exposure to a technology theme that has attracted enormous investment across the broader economy.

The company’s decision to pursue a public listing also comes after substantial private-market funding. The roughly $462 million it has raised since inception gives Iambic a significant financial base, but the IPO will provide additional capital to advance its clinical pipeline and expand its drug-discovery operations.

Iambic plans to list on the Nasdaq under the ticker “IAM.” J.P. Morgan, Jefferies, BofA Securities and Citigroup are serving as underwriters.

The offering will provide another test of whether investors are willing to assign public-market valuations to AI-enabled biotechnology companies before their leading drug candidates have reached late-stage clinical development.

For the broader IPO market, Iambic’s filing adds to evidence that the reopening of the U.S. listing window is uneven rather than uniform. Companies tied to sectors with identifiable acquisition demand or differentiated technology are finding investors even as higher yields and geopolitical risks make capital markets more selective.